Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To determine the maximum tolerated dose(s) (MTD) and the recommended Phase 2 dose(s) (RP2D)
of SAR245408 and MSC1936369B when combined in adult subjects with locally advanced or
metastatic solid tumors.
Secondary Objective:
- To characterize the safety and tolerability of SAR245408 and MSC1936369B combination
therapy administered orally to adult patients with locally advanced or metastatic solid
tumors
- To evaluate the pharmacokinetic (PK) profile of SAR245408 and MSC1936369B when used in
combination
- To evaluate the pharmacodynamic (PD) effect of the SAR245408/MSC1936369B combination by
assessing target and pathway inhibition